Freyr Solutions

Freyr Solutions

Cerca

Managing Dynamic Digital Label Content Across Multiple Markets

In today’s pharmaceutical industry, labeling is no longer a static document updated only at scheduled intervals. It has evolved into a dynamic and continuously changing source of information that must reflect the latest safety findings, regulatory requirements, and scientific advancements. Managing digital label content across multiple global markets creates both opportunities and...

Freyr Solutions

2026-05-18 05:19:54

Company Core Data Sheet and Its Significance in the Pharma

The pharmaceutical industry operates in an increasingly complex and highly regulated global environment, where products are developed, approved, and marketed across multiple regions. Ensuring consistency in product information across these markets can be challenging. This is where the Company Core Data Sheet (CCDS) plays a vital role. Acting as a global reference document, the CCDS consolidates...

Freyr Solutions

2026-05-18 04:58:10

Regulatory Publishing and Submissions in 2026

Regulatory Publishing and Submissions in 2026: From Operational Support to Strategic Advantage Regulatory publishing and submissions are experiencing a significant transformation. What was once viewed primarily as a technical, execution-driven activity has now become a critical element of broader regulatory strategy. As submission volumes grow and global regulatory submissions...

Freyr Solutions

2026-05-15 02:45:02

Scaling Regulatory Submissions Across North America and Europe

Scaling Regulatory Submissions Across North America and Europe As pharmaceutical companies expand globally, scaling regulatory submissions across North America and Europe has become more than a compliance requirement — it is now a strategic business priority. Managing global regulatory submissions across multiple regions involves increasing complexity due to varying regulatory frameworks,...

Freyr Solutions

2026-05-15 02:00:04

Transitioning to Proactive and Data-Driven Safety Management

Pharmacovigilance in 2026: A Shift Toward Proactive Drug Safety Pharmacovigilance (PV) in 2026 is undergoing a major transformation. Growing data volumes, rapid technological advancements, and increasing regulatory expectations are redefining how organizations approach drug safety management. Traditional PV models focused mainly on compliance and adverse event reporting are evolving into more...

Freyr Solutions

2026-05-15 01:50:35

Philippines Pharmaceutical Market Entry 2026

Malaysia Pharmaceutical Regulations 2026: Key NPRA Updates and Market Entry Considerations Manufacturers planning pharmaceutical market entry into Malaysia in 2026 must prepare for a series of important regulatory reforms introduced by the National Pharmaceutical Regulatory Agency (NPRA). Effective from 2025 onward, these updates will significantly impact product registration, pharmacovigilance...

Freyr Solutions

2026-05-13 09:49:03

Philippines Pharmaceutical Market Entry 2026

Major Regulatory Updates Shaping Market Entry in 2026 1. Revised Product Registration Framework Administrative Order (AO) No. 2024-0013, effective in 2025, significantly updates the registration process for pharmaceutical products and active pharmaceutical ingredients (APIs) intended for human use. The revised framework: Aligns submissions with ASEAN Common Technical Dossier (ACTD) and CTD...

Freyr Solutions

2026-05-13 09:47:14

ARTG Inclusion in Australia

Navigating ARTG Inclusion: Building a Smarter Regulatory Strategy for Australia Freyr supports pharmaceutical companies in navigating Australia’s highly regulated and commercially significant healthcare market. As regulatory expectations continue to evolve, gaining inclusion in the Australian Register of Therapeutic Goods (ARTG) has become more than a procedural requirement—it is...

Freyr Solutions

2026-05-13 04:15:45

Japan’s Drug Lag & Drug Loss

Japan’s Drug Lag and Drug Loss: Turning Regulatory Complexity into Strategic Opportunity Freyr helps pharmaceutical companies navigate one of the world’s most sophisticated healthcare markets—Japan. While Japan remains a highly attractive destination for innovative therapies, two major challenges continue to influence market access and regulatory planning: drug lag and drug...

Freyr Solutions

2026-05-13 04:13:38

Generic & Value-Added Medicines Opportunity in Africa

Africa’s Pharmaceutical Market: Emerging Opportunities for Generics and Value-Added Medicines Africa’s pharmaceutical sector is entering a new phase of growth, creating significant opportunities for generic drug manufacturers and developers of value-added medicines (VAMs). Rising healthcare demand, evolving regulatory systems, and increasing investment in local manufacturing are...

Freyr Solutions

2026-05-07 12:45:06

China’s Patent Linkage System & Impact on Drug Registration

China’s pharmaceutical regulatory landscape has undergone significant reform with the introduction of the patent linkage system, a critical mechanism shaping drug registration in China and market entry strategies for both innovators and generic manufacturers. Implemented under the amended Patent Law and associated measures, the system links patent status with marketing authorization...

Freyr Solutions

2026-05-06 04:16:27

FDA 2026 NAMs Guidance on Human-Relevant Evidence

The FDA’s March 2026 draft guidance on new approach methodologies (NAMs) is more than a policy statement; it is a signal that evidence from non-animal testing is moving closer to mainstream Regulatory decision-making. While the draft does not impose a blanket acceptance rule for sponsors, it clearly articulates a scientific framework that explains when and how NAMs can inform drug...

Freyr Solutions

2026-05-06 04:11:46

Mostra tutto